VRTX Q3 2026 Earnings Analysis
Vertex achieved 12% Q3 revenue growth across diversified products, raised FY2026 guidance to $13.15-$13.25B, and completed $9.0B Crinetics acquisition.
Key Metrics
Points clés
- Q3 revenue grew 12% YoY with balanced growth across CF, heme (CASGEVY), pain (JOURNAVX), rare endocrinology
- Raised FY2026 guidance to $13.15B-$13.25B after closing $9.0B Crinetics acquisition, 4th commercial pillar
- Q3 JOURNAVX prescriptions exceeded 750K, up 40%+ sequentially; preparing Nov 30 povitacept PDUFA launch
Écouter sur
Disponible en
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Vertex Pharmaceuticals' third quarter 2026 results, and this one is packed with news. I'm Alex.
And I'm Jordan. Vertex is quietly transforming from a cystic fibrosis company into something much bigger, and this quarter really drives that home.
Before we jump in, quick reminder: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Alright, let's get into the numbers.
Vertex posted 12% year-over-year revenue growth in Q3, with 10% growth domestically and 16% internationally. That's a nicely balanced global story. And they raised full-year guidance to a range of $13.15 billion to $13.25 billion.
What stood out to me is *where* that growth is coming from. Yes, cystic fibrosis is still the backbone—$3.3 billion in the quarter, up 8%—but the real excitement is in the newer stuff. CASGEVY, their gene therapy for sickle cell disease and beta thalassemia, hit $99 million, up 30% sequentially. And JOURNAVX, the non-opioid pain medicine, brought in $58 million with over 750,000 prescriptions in the quarter alone.
JOURNAVX is actually now the number one prescribed branded oral analgesic in the U.S. That's a big milestone for a drug that's trying to change decades of prescribing habits around pain management.
Right, and management is playing a long game there. They're keeping a patient support program running through 2027 to make sure patients get access even before insurance fully catches up. That's actually suppressing reported revenue right now because of gross-to-net dynamics, but it sets up for a cleaner growth trajectory once that program sunsets.
Now here's the headline strategic move: Vertex closed its $9 billion acquisition of Crinetics Pharmaceuticals, which gives them Palsonify, an oral treatment for acromegaly. This is officially their fourth commercial pillar, and management says they're on the verge of a fifth—renal medicine—pending a PDUFA decision on povitacept for IgA nephropathy on November 30th. That's just weeks away.
That's the part I find most interesting. Vertex is essentially building a five-pillar company in real time—CF, hematology, pain, rare endocrine, and soon renal. Palsonify only contributed for one month post-close but still brought in $10 million in September alone, and full Q3 contribution was about $24 million. Early metrics look healthy too—roughly 500 endocrinologists are already writing prescriptions, with leading market share among new and switching patients.
On the earnings side, non-GAAP net income came in at $1.21 billion, or $4.76 per share. Gross margin was strong at 85.6% on a non-GAAP basis. But operating expenses are climbing—they revised full-year opex guidance up to approximately $6 billion, largely to absorb Crinetics integration costs and continued commercial scale-up for these launches.
That's the trade-off here. Vertex is spending aggressively to support five simultaneous launches and a major acquisition integration. SG&A was up 51% year-over-year in the quarter, with most of that going toward commercial infrastructure for povitacept, JOURNAVX, and Palsonify.
Let's talk about the Q&A, because there were some meaty exchanges. Analysts pushed hard on povitacept—there was even a citizen's petition raising questions about IgG monitoring requirements. CEO Reshma Kewalramani addressed it head-on, noting that serious infection rates were balanced between drug and placebo arms in their trial, and that everything happening with the FDA review is proceeding as expected.
The other big thread was around anaxaplin, their kidney disease candidate in the AMPLITUDE trial. Analysts wanted to understand what a "win" looks like, and Reshma was crystal clear: the FDA's accelerated approval pathway hinges on statistically significant improvement in GFR—that's kidney filtration rate—not just proteinuria reduction. She expressed real confidence here, drawing parallels to how APRIL/BAFF inhibitors in IgA nephropathy have shown that *how* you reduce protein matters, not just how much.
And there was a fun moment of transition acknowledgment too—this was CFO Charles Wagner's last earnings call in that role. He's moving to a COO-focused position, with Jonathan Pool stepping in as CFO starting in 2027. Reshma gave him a warm send-off, noting he helped grow the company from $4 billion in revenue in 2019 to over $13 billion today.
It's a good encapsulation of the Vertex story, honestly. This isn't the same company it was even three years ago.
So what does this mean for investors going forward? The near-term catalyst everyone's watching is that November 30th PDUFA date for povitacept. If approved, Vertex would be entering its fifth disease area in a matter of weeks, which is a remarkable pace of diversification for a company this size.
And longer-term, keep an eye on the AMPLITUDE interim analysis expected early next year—that could set up accelerated approval for anaxaplin in kidney disease. Plus there's chronic pain data coming mid-2027, and more next-gen CF corrector data expected as well. There's a lot of pipeline catalysts stacked up over the next twelve months.
It really does feel like Vertex is in the middle of its most ambitious expansion phase yet.
Before we wrap up—everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Well said. Lots to watch heading into that November 30th decision and beyond.
This is shaping up to be a pivotal stretch for Vertex. We'll be back to break down what happens next.
Thanks for listening to Beta Finch—see you next time!